Case {#sec1-1}
====

A 75-year-old Caucasian male developed redness on the surface of the right eye (OD) \[[Fig. 1a](#F1){ref-type="fig"}\] that persisted for 6 months. Surgical excision revealed amelanotic conjunctival melanoma without primary acquired melanosis \[[Fig. 1b](#F1){ref-type="fig"}\]. Eight years later, he noted mild recurrent redness on the opposite side of the OD, appearing as an inflamed pingueculum \[[Fig. 1c](#F1){ref-type="fig"}\].

![An amelanotic mass with feeder and fine intrinsic vessels at the 1 o'clock bulbar conjunctiva of the right eye (a). Histopathology confirmed the diagnosis of conjunctival melanoma (b). Years later a new lesion appeared at the 9 o'clock limbus resembling a pingueculum (c). Histopathology again revealed amelanotic melanoma (d)](IJO-67-1792-g001){#F1}

What is Your Next Step? {#sec1-2}
=======================

Prescribe topical nonsteroidal anti-inflammatory drugsPrescribe topical corticosteroidsPerform cryotherapyPerform "no touch" surgical excision.

Findings {#sec1-3}
========

"No touch" surgical excision (D) was performed, as there was suspicion for amelanotic melanoma recurrence. Histopathology revealed a segment of conjunctiva containing nests and sheets of atypical small epithelioid and spindle amelanotic melanocytes in the substantia propria, consistent with recurrence of the previously diagnosed conjunctival melanoma \[[Fig. 1d](#F1){ref-type="fig"}\]. All margins were clear. The specimen was sent for biomarker testing, which revealed pathogenic *NRAS* mutation and no mutation in *BRAF* or *c-KIT* biomarkers.

Diagnosis {#sec1-4}
=========

Conjunctival amelanotic melanoma.

Correct Answer: {#sec1-5}
===============

**D.**

Discussion {#sec1-6}
==========

Conjunctival malignant melanoma (CMM) represents 0.25% of melanomas.\[[@ref1]\] Typical management includes complete surgical resection and cryotherapy.\[[@ref2]\] Adjuvant therapy is considered to prevent tumor recurrence and metastasis.\[[@ref2]\] Wong *et al.* reported up to 45% local recurrence and 42% systemic metastasis in 5 years.\[[@ref1]\] Similar to cutaneous melanoma, CMM has been associated with *BRAF, c-KIT*, and *NRAS* mutations.\[[@ref2]\] *NRAS* mutations have been associated with more aggressive disease and decreased survival.\[[@ref3]\] While no approved *NRAS*-specific targeted therapies are currently available, immune-based therapies such as interleukin-2 (IL-2), anti-CTLA4 antibody (ipilimumab), and anti-PD1 treatment (nivolumab and pembrolizumab) are now first-line treatments for *NRAS*-mutated cutaneous melanoma.\[[@ref3]\]
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